These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 19938903

  • 1. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [Abstract] [Full Text] [Related]

  • 2. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 3. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN, Eschenhagen T.
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [Abstract] [Full Text] [Related]

  • 4. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE.
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [Abstract] [Full Text] [Related]

  • 5. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 6. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I.
    Med Monatsschr Pharm; 2011 May 01; 34(5):154-8. PubMed ID: 21644373
    [Abstract] [Full Text] [Related]

  • 7. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 01; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 8. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May 01; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

  • 9. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D'Aloia A, Curnis A.
    Cardiovasc Ther; 2013 Oct 01; 31(5):e55-62. PubMed ID: 23398692
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y, Dobrev D.
    Vasc Health Risk Manag; 2013 Oct 01; 9():165-75. PubMed ID: 23637539
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J.
    J Clin Pharmacol; 2009 Jan 01; 49(1):17-29. PubMed ID: 18927241
    [Abstract] [Full Text] [Related]

  • 12. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
    Ehrlich JR, Nattel S.
    Curr Opin Cardiol; 2009 Jan 01; 24(1):50-5. PubMed ID: 19077816
    [Abstract] [Full Text] [Related]

  • 13. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
    Wettwer E, Christ T, Endig S, Rozmaritsa N, Matschke K, Lynch JJ, Pourrier M, Gibson JK, Fedida D, Knaut M, Ravens U.
    Cardiovasc Res; 2013 Apr 01; 98(1):145-54. PubMed ID: 23341576
    [Abstract] [Full Text] [Related]

  • 14. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
    Tanaka H, Hashimoto N.
    Cardiovasc Drug Rev; 2007 Apr 01; 25(4):342-56. PubMed ID: 18078434
    [Abstract] [Full Text] [Related]

  • 15. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 16. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA, Lau YC, Lip GY.
    Expert Opin Pharmacother; 2014 Apr 22; 15(6):865-72. PubMed ID: 24617913
    [Abstract] [Full Text] [Related]

  • 17. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct 22; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 18. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M.
    Am J Health Syst Pharm; 2010 Jul 15; 67(14):1157-64. PubMed ID: 20592320
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.
    J Clin Pharmacol; 2012 Jul 15; 52(7):1042-53. PubMed ID: 21659624
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.